ClinicalTrials.gg
Status unknownNCT01610440Updated Nov 30, 2012

Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Duchenne Muscular Dystrophy

A Phase 1/2 interventional study of human umbilical cord mesenchymal stem cells in Duchenne Muscular Dystrophy, sponsored by Shenzhen Beike Bio-Technology Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 5 Years to 12 Years. Per ClinicalTrials.gov, last updated 2012-11-30.

Sponsored by Shenzhen Beike Bio-Technology Co., Ltd. · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2012), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
5 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Muscular Dystrophy, Duchenne with a site in China — 5 open to participants now, 10 under way, 1 of them phase 3. Muscular Dystrophy, Duchenne · China.

Planned enrollment
10th of 17
15 · median 20
Started
2011
the only one that year
Phase 1/2
Only one
of the 19
Registered
1st of 19
by date

Among the 19 studies in Muscular Dystrophy, Duchenne with a site in China, this one is the 10th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2011, is the only one in phase 1/2, and was the 1st registered.

Muscular Dystrophy, Duchenne

481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

5 of the 19 studies in Muscular Dystrophy, Duchenne with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 12 take healthy volunteers.

This study: 5 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Muscular Dystrophy, Duchenne with a site in China, or all of them as a file.
02

Study summary

Duchenne muscular dystrophy (DMD), an X-linked recessive genetic disease always progressed slowly,tends to leading proximal skeletal muscle atrophy and weakness of limbs, as well as impaired respiratory muscle and cardiac muscle. To a large extent, patients always lose motor function gradually and die for heart failure or severe infection at the end stage of DMD. At present, the treatment strategy relies on heteropathy accompanied with rehabilitation training. However, the therapeutic effect remains extremely limited.

Human umbilical cord mesenchymal stem cells (hUC-MSCs) have been evidenced to improve motor function, increase muscle strength and reduce abnormal levels of related enzymes, such as creatine kinase (CK), lactate dehydrogenase (LDH), alanine aminotransferase (ALT) and aspartate aminotransferase (AST). This study is aimed to explore the safety and efficacy of hUC-MSCs transplantation for DMD.

Read the detailed description

This study is designed to investigate the safety and efficacy of human umbilical cord mesenchymal stem cells transplantation in patients with progressive muscular dystrophy.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • Duchenne muscular dystrophy
  • Human Umbilical Cord Mesenchymal Stem Cells
04

Who can participate

Ages eligible
5 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 5-12 years
  • Clinical manifestation, enzymology, electromyogram, gene type confirmed the diagnose of Duchenne muscular dystrophy
  • Sign the consent form and follow the clinic trail procedure

Exclusion criteria

Exclusion Criteria:

  • Not Duchenne muscular dystrophy
  • Any history of to serum products,or other know drug and food allergy
  • Combined Pneumonia or other Severe systemic bacteria infection
  • +, TPPA +, patients diagnosed as or
  • Tumor Markers +
  • Severe psychotic patients, cognitive dysfunction
  • Coagulation disorders
  • Uncontrolled hypertension after treatment,blood pressure≥180mmHg/110 mmHg
  • Other severe systemic or organic disease
  • Enrollment in other trials in the last 3 months
  • Received any stem cell therapy in past 6 months
  • Other criteria that investigator consider improper for inclusion
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Participants will be given rehabilitation therapy plus human umbilical cord mesenchymal stem cells transplantation with one year follow-up

    Biological: human umbilical cord mesenchymal stem cells

Interventions

06

What researchers measure

Primary outcomes

  1. Activities of Daily Living(ADL)scale

    Time frame: 1 year after treatment

Secondary outcomes

  1. Incidences of Adverse Event and Serious Adverse Event

    Time frame: 1 year after treatment

  2. Change from baseline in CK

    Time frame: 1 year after treatment

  3. Change from baseline in LDH

    Time frame: 1 year after treatment

  4. Change from baseline in ALT

    Time frame: 1 year after treatment

  5. Change from baseline in AST

    Time frame: 1 year after treatment

  6. Change from baseline to manual muscle test(MMT)

    Time frame: 1 year after treatment

  7. Change from baseline in electromyography(EMG)

    Time frame: 1 year after treatment

07

Study locations

1 of 1 sites recruiting
  • The Second Affiliated Hospital of Kunming Medical College
    Kunming, Yunnan 650031, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Mar 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2012
First posted
Jun 4, 2012
Start
Oct 2011
Primary completionEst.
Mar 2013
CompletionEst.
Oct 2013
Last update
Nov 30, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01610440
Lead sponsor
Shenzhen Beike Bio-Technology Co., Ltd.
Collaborators
The Second Affiliated Hospital of Kunming Medical University
Responsible party
Sponsor
First posted
Jun 4, 2012
Start date
Oct 2011
Primary completion
Mar 2013 (estimated)
Completion
Oct 2013 (estimated)
Last update
Nov 30, 2012

Study contacts

Liqing Yao
principal investigator · The Second Affiliated Hospital of Kunming Medical University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion